A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

Clinical trial NCT07587242 · RECRUITING

Trial details

NCT number: NCT07587242
Sponsor: Avidity Biosciences, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Muscular Dystrophies Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)Muscular Disorders, Atrophic Muscular Disease Musculoskeletal Diseases Neuromuscular Diseases (NMD)Nervous System Diseases Genetic Diseases X-Linked Hereditary Neonatal Disease Duchene Muscular Dystrophy

Start date: 2026-08-01
Primary completion: 2029-05-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.